Engelhardt Eva Anette
SEC Form 4 history across 1 companies, 7 transactions and 1 filings.
Available history · Sep 04, 2026 – Sep 06, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
BIO BIO.BBIO-RAD LABORATORIES, INC. | Engelhardt Eva AnetteEVP · PRES · CDG | M · exerciseDerivative securitySEC filing ↗ | $0View disclosure → | |
BIO BIO.BBIO-RAD LABORATORIES, INC. | Engelhardt Eva AnetteEVP · PRES · CDG | M · exerciseDerivative securitySEC filing ↗ | $0View disclosure → | |
BIO BIO.BBIO-RAD LABORATORIES, INC. | Engelhardt Eva AnetteEVP · PRES · CDG | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
BIO BIO.BBIO-RAD LABORATORIES, INC. | Engelhardt Eva AnetteEVP · PRES · CDG | F · withholdingSEC filing ↗ | -$187kView disclosure → | |
BIO BIO.BBIO-RAD LABORATORIES, INC. | Engelhardt Eva AnetteEVP · PRES · CDG | M · exerciseSEC filing ↗ | $0View disclosure → | |
BIO BIO.BBIO-RAD LABORATORIES, INC. | Engelhardt Eva AnetteEVP · PRES · CDG | F · withholdingSEC filing ↗ | -$142kView disclosure → | |
BIO BIO.BBIO-RAD LABORATORIES, INC. | Engelhardt Eva AnetteEVP · PRES · CDG | M · exerciseSEC filing ↗ | $0View disclosure → |
Latest Form 4 facts
Quick context from source filings
No latest transaction fact is available.
No open-market insider purchase is available.
No open-market insider sale is available.
Monthly open-market activity
Last 1 reported months · purchases and sales
No open-market purchases or sales in this history.
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | $0.00 | $0.00 | $0.00 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
4 observations · Sep 5, 2026 – Sep 6, 2026. Window ends at the latest available report, not today.
View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Sep 5, 2026 | 1,530 | Sep 9, 2026 | View transaction |
| Sep 5, 2026 | 1,161 | Sep 9, 2026 | View transaction |
| Sep 6, 2026 | 2,313 | Sep 9, 2026 | View transaction |
| Sep 6, 2026 | 1,828 | Sep 9, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Engelhardt Eva Anette Insider Activity FAQ
SEC Form 4 context
Who is Engelhardt Eva Anette?
Engelhardt Eva Anette is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002024911.
Which companies has Engelhardt Eva Anette reported transactions for?
BIO-RAD LABORATORIES, INC.
When was Engelhardt Eva Anette's latest insider buy?
No open-market insider purchase is available for this period.
When was Engelhardt Eva Anette's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.